New Covid Variant Called JN.1

(Scypre.com) – The Centers for Disease Control and Prevention (CDC) estimates that the new COVID-19 variant, referred to as JN.1, now accounts for approximately 44.1% of COVID-19 cases in the United States. This marks a significant increase from the 21.3% reported for the week ending Dec. 9, post-Thanksgiving. The Northeast region, covering New Jersey and New York, shows the highest prevalence of JN.1, constituting 56.9% of cases.

The CDC expressed concern about the variant’s rapid growth, suggesting that it may be either more transmissible or adept at evading the immune system. However, the potential impact on infection rates or hospitalizations remains uncertain. The World Health Organization (WHO) elevated JN.1 to a “variant of interest,” the second-highest classification, following its widespread increase in several countries.

Despite the absence of reported severe symptoms, the unique accumulation of mutations in JN.1, inherited from its highly mutated parent BA.2.86, has raised alarms among health authorities. Previously, BA.2.86 struggled to gain global traction, but the additional mutations in JN.1 have altered its trajectory, potentially making it more transmissible.

The Biden administration, in contrast to the WHO, has chosen to categorize JN.1 alongside its parent BA.2.86 as a “variant being monitored” rather than a standalone “variant of interest.” The CDC commits to continuous monitoring and updates as new information emerges.

Early studies, cited by the WHO, suggest that JN.1 may display higher immune evasion compared to its parent BA.2.86. However, current COVID-19 vaccines are still deemed effective against it. Vaccine manufacturers, such as Novavax and Pfizer, are conducting tests to assess their vaccines’ efficacy against JN.1.

Dr. Jeanne Marrazzo, head of the National Institute of Allergy and Infectious Diseases, emphasizes the need for vigilance, stating that if there is a significant reduction in vaccine protection, swift action will be necessary. The WHO indicates that early data from Belgium and Singapore suggest JN.1 may have similar or reduced hospitalization risks compared to other strains.

While the CDC observes an increase in COVID-19 emergency department visits and hospitalizations, the current trends are not as severe as the record surge experienced in the winter of 2021-2022. The situation is being closely monitored, particularly regarding key endpoints like hospitalizations and deaths.